A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index ≥27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease.

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

开始日期2024-04-30

申办/合作机构

Eli Lilly & Co.

NCT06354660 / Recruiting临床3期

A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

开始日期2024-04-10

申办/合作机构

Eli Lilly & Co.

NCT06313528 / Recruiting临床1期

A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

开始日期2024-03-20

申办/合作机构

Eli Lilly & Co.

100 项与瑞他鲁肽相关的临床结果

登录后查看更多信息

100 项与瑞他鲁肽相关的转化医学

登录后查看更多信息

100 项与瑞他鲁肽相关的专利（医药）

登录后查看更多信息

项与瑞他鲁肽相关的文献（医药）

2024-03-01·Peptides

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Article

作者: Flatt, Peter R ; Conlon, J Michael ; Bailey, Clifford J

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies. Most of these studies have been conducted with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, which is available as a once weekly subcutaneous injection and once daily tablet, and the once weekly injected dual agonist tirzepatide, which interacts with receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In individuals with T2DM these therapies have achieved reductions of glycated haemoglobin (HbA1c) by > 2% and lowered body weight by > 10%. In some studies, these agents tested in non-diabetic, obese individuals at much higher doses have lowered body weight by > 15%. Emerging evidence suggests these agents can also offer cardio-protective and potentially reno-protective effects. Other incretin-based peptide therapies in early clinical development, notably a triple GLP-1/GIP/glucagon receptor agonist (retatrutide) and a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), have shown strong efficacy. Although incretin therapies can incur adverse gastrointestinal effects these are for most patients mild-to-moderate and transient but result in cessation of treatment in some cases. Thus, the efficacy of new incretin-based peptide therapies is enhancing the opportunity to control body weight and blood glucose and improve the treatment of T2DM and obesity.

2024-01-22·Expert opinion on pharmacotherapy

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Review

作者: Mondoh, Alvin ; Le Roux, Carel

INTRODUCTION:

Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.

AREAS COVERED:

Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.

EXPERT OPINION:

The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.

International journal of obesity (2005)

What is the pipeline for future medications for obesity?

Review

作者: Melson, Eka ; Papamargaritis, Dimitris ; Ashraf, Uzma ; Davies, Melanie J

Abstract:

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15–17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.

175

项与瑞他鲁肽相关的新闻（医药）

2024-06-21

·药研网

2024 ADA | 瀚森小分子GLP-1、信达(玛仕度肽)最新研究成果公布

备受瞩目的2024年美国糖尿病学会（ADA）年会于6月21-24日在美国奥兰多召开，大会不仅包括在降糖领域的新型降糖药司美格鲁肽、度拉糖肽等最新研究成果，还展示了大火的减重领域替尔泊肽、玛仕度肽等最新发现，可谓是“百花争艳”（文末附清单）。翰森制药小分子GLP-1药物翰森制药自主研发的小分子GLP-1药物HS-20094（GLP-1R/GIPR双靶点激动剂）Ⅱ期临床研究数据以壁报+电子壁报现场问答形式在大会发布。数据显示，HS-20094在2型糖尿病受试者中具有良好的安全性、耐受性特征，数据展现出优秀的降糖减重疗效。具体信息如下： >>研究成果在2型糖尿病受试者中评价HS-20094多次给药的安全性、耐受性、药代动力学和药效学的随机、双盲、安慰剂和阳性对照的Ⅱa期临床试验壁报编号：733-P >>研究设计： • 随机、双盲、安慰剂和阳性（司美格鲁肽）对照的Ⅱa期临床试验； • 旨在评估HS-20094注射液在2型糖尿病受试者中多次给药的安全性、耐受性、药代动力学和药效动力学特征； • 研究分组：HS-20094 5mg组、HS-20094 10mg组、HS-20094 15mg组、安慰剂组、司美格鲁肽组； • 给药方式：每周一次，皮下注射，共给药4次。 >>研究结果：共54例受试者接受了至少一次给药，其中HS-20094组、司美格鲁肽组和安慰剂组分别为36例、9例和9例。安全性方面：在2型糖尿病受试者中，HS-20094的总体安全性和耐受性良好；最常见的胃肠道的AE，包括腹胀、恶心、腹泻等。AE严重程度主要为轻中度（98%），仅HS-20094 5mg组发生1例与研究药物无关的SAE；HS-20094 10mg组、HS-20094 15mg组、安慰剂组和司美格鲁肽组在研究的各个阶段均未发生SAE。本研究未发生严重低血糖事件；未发生导致退出试验的AE；未发生导致剂量调整的AE；未发生导致死亡的AE。药代动力学方面：HS-20094连续4次皮下注射5-15mg后，平均Tmax为16h-24h，平均半衰期T1/2为142h-168h，暴露量(Cmax 和AUC)近似呈剂量比例化增加。药效动力学方面： >>降糖方面：给药4周后，HS-20094各剂量组Day23 OGTT血糖AUC0-2h均较基线呈剂量依赖性地下降， HS-20094各剂量组Day23 OGTT胰岛素AUC0-2h和 C肽AUC0-2h均较基线增加。以上HS-20094各剂量组的变化幅度显著优于安慰剂组。HS-20094 15mg组较基线下降幅度高于司美格鲁肽组。 HS-20094各剂量组Day29 HbA1c均较基线下降，下降幅度呈剂量依赖性，且均显著高于安慰剂组。 >>减重方面： 4周研究周期中，HS-20094各剂量组的体重和体重指数均呈持续下降，下降幅度呈剂量依赖性，且下降幅度均显著优于安慰剂组。HS-20094 15mg组体重较基线下降幅度高于司美格鲁肽组。 >>研究结论: 以上数据表明，HS-20094各剂量在降糖和减重上均显著优于安慰剂组，HS-20094与司美格鲁肽比较数据见后续发布。目前翰森制药已在国内启动并加速推进HS-20094针对2型糖尿病患者、超重/肥胖者的后期研究，以期为上述类型患者带来更多福音。信达生物玛仕度肽48周减重14% 玛仕度肽是信达生物与礼来共同推进的一款GLP-1R和GCGR双激动剂。近期，玛仕度肽首个减重III期注册临床研究GLORY-1数据将以重磅进展（Late Breaking）口头报告和大会壁报形式报告。 ADA官方期刊Diabetes网站公布的GLORY-1研究摘要 >>研究设计随机、双盲、安慰剂对照3期试验（NCT05607680）评估每周一次的GLP-1R和GCGR双激动剂在中国超重或肥胖参与者中的疗效和安全性。纳入600例受试者，按1:1:1的比例随机分配至mazdutide 4mg组、mazdutide 6mg组或安慰剂组，共治疗48周。主要终点是第32周时受试者体重相对基线的百分比变化以及体重相对基线下降≥5%的受试者比例。 >>研究结果：相比于安慰剂组，4mg剂量组减重10.72%，6mg剂量组减重13.14%。关键次要终点，治疗48周减重百分比，4mg剂量组减重11.58%，6mg剂量组减重14.37%。同时，治疗48周心血管风险参数也都显著降低，相比于安慰剂组，玛仕度肽治疗组血压降低6.75mmHg，甘油三酯降低0.52mmol/L，总胆固醇降低0.45mmol/L，LDL-C降低0.31mmol/L，血尿酸降低50.75mmol/L，ALT降低10U/L。Mazdutide达到了共同主要终点和所有关键的次要终点，在体重变化、减肥目标和多种心脏代谢危险因素的改善方面优于安慰剂（表）。安全性方面，玛仕度肽耐受性良好，4mg、6mg剂量组的停止治疗比例分别为1.5%、0.5%，安慰剂组这一比例为1.0%。最常报告的不良事件是胃肠道不良事件，严重程度大多为轻度至中度。 >>研究结论：在中国超重或肥胖的成年人中，玛仕度肽可显著降低体重和心脏代谢危险因素。对于超重或肥胖且肝脂肪变性的中国成年人，玛仕度肽4mg和6mg可显著降低LFC。信达生物还公布了玛仕度肽9mg高剂量二期临床的最新数据，治疗24周减重15.4%，肝脏脂肪减少73.3%。玛仕度肽9 mg显示出强大的体重减轻和显着的肝脏益处。三期临床GLORY-1的详细数据可以看到，玛仕度肽不仅减重效果显著，同时对降脂效果尤其显著，这也体现了GCGR靶点的优势。近日，礼来在Nature Medcine上发表了GLP-1R/GCGR/GIPR受体三重激动剂Retatrutide治疗MASLD的IIa期研究数据。Retatrutide在降低MASLD患者的肝脏脂肪含量上有非常不错的效果，最高降幅可达86%。勃林格殷格翰的GLP-1R/GCGR双靶点激动剂即同时推进降糖、减重、NASH三项三期临床。为助力GIP、GLP-1和GCG相关药物的研发，吉满生物构建了基于cAMP信号通路的多种GIPR、GLP-1R和GCGR过表达细胞模型，可以进行体外GIPR、GLP-1R和GCGR激动剂和抗体药物的筛选。 2024 ADA重磅研究公布 ➤12-PUB - Tirzepatide—日本真实世界 2 型糖尿病应用中的疗效、安全性和满意度 ➤120-OR - Tirzepatide在 SURMOUNT-2 中实现血糖、血压和脂质目标综合终点 ➤13-PUB - Tirzepatide在实体器官移植患者中的安全性和有效性 ➤140-OR - 2 型糖尿病患者接受达格列净治疗后冠状动脉血流储备增加在四年后得以维持——一项为期四年的 DAPAHEART 随访研究 ➤1400-P – SGLT-2i对非酒精性脂肪肝合并 2 型糖尿病患者的肝脏疗效 ➤1547-P – SGLT-2i卡格列净随着衰老调节下丘脑功能 ➤1550-P - 达格列净联合艾塞那肽治疗 2 型糖尿病 (T2D) 患者期间 β 细胞功能的变化 ➤1638-P - 二甲双胍增强上小肠脂质感应，以独立于 GDF15 释放来调节食物摄入量 ➤1660-P - Tirzepatide治疗 1 型糖尿病成人肥胖症的疗效和安全性——梅奥诊所的经验 ➤1665-P - Survodutide 在 2 型糖尿病或超重/肥胖患者中的 I 期和 II 期研究中的葡萄糖生物标志物分析 ➤1676-P - 在 SURMOUNT-3 试验中，Tirzepatide改善了肥胖或超重成人的精神和社会心理功能 ➤1691-P - 接受 2.4 mg 司美格鲁肽治疗的肥胖或超重患者的临床结果——美国真实世界回顾性队列研究 (SCOPE 2) ➤1708-P - 口服司美格鲁肽对 BMI ≥ 25 kg/m^2 的 2 型糖尿病患者的血糖控制和减肥效果——一项为期六个月的真实世界研究 ➤1856-LB - Mazdutide对中国超重或肥胖参与者的疗效和安全性（GLORY-1） ➤1857-LB - Mazdutide改善中国超重或肥胖参与者的肝脏脂肪变性——GLORY-1 的探索性分析 ➤1866-LB - Mazdutide 9 mg 在 BMI≥30 kg/m^2中国成年人中的 2 期研究 ➤1869-LB - iGlarLixi 与 IDegAsp 对口服降糖药 (OAD) 控制不佳的中国 2 型糖尿病 (T2D) 患者的疗效和安全性——SoliD 随机对照试验 ➤1882-LB - 根据血糖波动性比较每周一次胰岛素 Icodec 与每日一次胰岛素 Degludec 在 1 型糖尿病中的疗效和安全性结果 - ONWARDS 6 事后分析参考资料： 2024 ADA、医脉通等 End 声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载/商务/投稿 | 联系微信 wfj_GM 商务合作稿件征集点击了解详情往期回顾 1 5月| 20家药企裁员（附名单） 2 18亿美元，ADC又出海! 宜联生物宣布新授权 3 2024 ASCO| 默沙东/科伦TROP2 ADC、信达、礼新CLDN18.2 ADC数据公布

临床结果临床2期AACR会议

2024-06-16

·医药魔方

肝脏脂肪含量降低86%！礼来GLP-1R/GCGR/GIPR激动剂II期研究数据亮眼

近日，礼来在《Nature Medcine》期刊上发表了GLP-1R/GCGR/GIPR激动剂Retatrutide（LY3437943）治疗代谢功能障碍相关脂肪性肝病（MASLD，旧称非酒精性脂肪性肝病（NASLD））的IIa期研究（NCT04881760）数据。总体而言，Retatrutide在降低MASLD患者的肝脏脂肪含量上有非常不错的效果，最高降幅可达86%。从2021年5月20日至2022年11月22日，共338例患者入组接受了Retatrutide（1/4/8/12mg，每周1次）或安慰剂治疗。其中98例（29.1%）患者满足肝脏脂肪含量≥10%（通过磁共振成像质子密度脂肪分数（MRI-PDFF）评估）的标准，被纳入MASLD子研究。子研究的疗效和安全性分析人群包括98例患者，其基线平均肝脏脂肪含量为19.1%。结果显示，在24周内，大部分患者的肝脏脂肪含量均显著下降。治疗24周后，与安慰剂组相比，Retatrutide所有剂量组患者的相对肝脏脂肪含量降低幅度更大（P<0.001）。来源：《Nature Medcine》治疗24周，最低剂量（1mg）组分别有71%、43%和22%患者的肝脏脂肪含量至少下降了30%、50%和70%，最高剂量（12mg）剂量组分别有100%、100%和80%患者的肝脏脂肪含量至少下降了30%、50%和70%。来源：《Nature Medcine》治疗48周，最低剂量（1mg）组分别有82%、65%和48%患者的肝脏脂肪含量至少下降了30%、50%和70%，最高剂量（12mg）剂量组分别有100%、100%和93%患者的肝脏脂肪含量至少下降了30%、50%和70%。来源：《Nature Medcine》治疗24周，各剂量组肝脏脂肪含量<5%的患者比例分别为27%、52%、79%和86%；治疗48周，1mg、8mg和12mg剂量组这一比例均有所上升，分别为57%、89%和93%，而4mg剂量组这一比例下降至29%。来源：《Nature Medcine》除了肝脏脂肪含量显著降低以外，Retatrutide组患者的体重、腰围、腹部内脏脂肪组织（VAT）含量、腹部皮下脂肪组织（ASAT）含量等指标也有所改善。来源：《Nature Medcine》 MASLD是世界上最常见的慢性肝病之一，其全球患病率已达到38%。MASLD进一步恶化会进展为代谢功能障碍相关脂肪性肝炎（MASH，旧称非酒精性脂肪性肝炎（NASH）），导致患者的肝纤维化程度加重，最终导致肝硬化，甚至可能引发肝癌。经过长时间的探索，MASH领域已迎来治疗突破，但MASLD领域的积极进展仍不多，相关临床研究数据屈指可数。在研药物MASLD疗效一览注：医药魔方整理 GLP-1类药物是近几年来在慢性肝病领域表现非常不错的药物，单靶和双靶药物均已取得积极进展（见：替尔泊肽攻取NASH再进一步）。此次Retatrutide在针对MASLD的II期研究中取得积极结果也让GLP-1靶点在慢性肝病治疗上的前景更加明朗。从目前的数据来看，Retatrutide在低剂量下即可达到与其它靶向药物相当的肝脏脂肪含量降低效果，这一点将为其创造竞争优势。期待Retatrutide未来的表现。参考资料： Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Copyright © 2024 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

临床结果

2024-06-13

·PRNewswire

The American Diabetes Association Kicks Off the 84th Scientific Sessions with Breakthrough Diabetes Research

Leading Diabetes Scientific Sessions Meeting Will Present Groundbreaking Data on Key Topics Including: Obesity, Technology, AI Health and the Latest in Diabetes Innovation ORLANDO, Fla., June 13, 2024 /PRNewswire/ -- From June 21–24, the American Diabetes Association® (ADA) will host the 84th Scientific Sessions in Orlando, FL. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening more than 11,000 leading physicians, scientists, researchers and health care professionals from around the globe. The hybrid meeting will feature the latest scientific findings in diabetes, including more than 200 sessions and 2,000 original research presentations at the Orange County Convention Center. Diabetes is among the top 10 leading causes of death in the United States, with more than 1.4 million new cases diagnosed each year. Over the past 20 years, the number of adults diagnosed with diabetes has more than doubled due to factors like increased obesity, weight gain and aging. During the annual meeting, the ADA is highlighting the latest cutting-edge advances in diabetes research and care. Among the key themes, you can expect: Obesity/weight-loss drugs: Obesity impacts 42% of American adults and contributes to up to 53% of the new cases of diabetes each year. This comes amid a surge of increased use of weight-loss drugs, with almost two million people in the U.S. taking semaglutide medications in 2021 —more than three times as many as in 2019. This year's meetings will feature several clinical studies addressing obesity treatment including groundbreaking data on glucagon-like peptide-1 (GLP-1) drugs and their impact on not only obesity and diabetes, but sleep apnea, kidney outcomes, and more. This will include data on Food and Drug Administration (FDA)-approved GLP-1 drugs such as Tirzepatide and a large number of GLP-1 drug candidates at various stages in the research pipeline, including Retatrutide, Pemvidutide and oral Ecnoglutide. Technology and AI: Innovative technologies and solutions are transforming diabetes management, offering new possibilities for improved patient outcomes and more personalized care. Studies will highlight advancements on solutions such as automated insulin delivery (AID) systems and new research on continuous glucose monitors (CGMs). Innovation: On Saturday, June 22 from 4:30-6:00 p.m. ET, the Innovation Challenge, which debuted in 2023, will once again invite emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determine which contestants will earn a private audience with potential funders. "As we commence the 84th Scientific Sessions, we are proud of our program that underscores our commitment to addressing the multifaceted challenges of diabetes," said Robert Gabbay, MD, PhD, the ADA's chief scientific and medical officer. "This year's program reflects our dedication to advancing research, fostering innovation, and ultimately improving the lives of those affected by diabetes. We look forward to an engaging and impactful event that will inspire and drive the future of diabetes care, at a pivotal time of pharmacological and technological advances in the field." Other notable topics and themes highlighted in the presentations at the 84th Scientific Sessions include eye health, health disparities, diabetes and obesity related cancers, and early risk monitoring. Most sessions, in addition to the 60-plus livestreamed sessions, will be available for on-demand viewing for attendees following the meeting through August 26. "This year's Scientific Sessions is set to highlight the latest and greatest advances in diabetes research with an exceptional, data-driven program," said Alice Y.Y. Cheng, MD, FRCPC, chair of the 84th Scientific Sessions Planning Committee. "Whether you're joining us in-person or virtually, you'll have the opportunity to engage with leading experts, participate in dynamic discussions, and gain valuable insights that will drive the future of diabetes care." Learn more about the 84th Scientific Sessions. For access to program navigation, educational session information, news updates, abstracts, and exhibitor information, the 2024 ADA Scientific Sessions mobile app and the online planner are your go-to meeting resources. For more information, please contact the ADA Scientific Sessions media at [email protected]. Embargo Policy: Oral presentations: Oral presentations are embargoed from the time of submission until the start of their presentation at the 84th Scientific Sessions. Symposiums (including late-breaking symposiums): Symposiums and presentations within symposiums are embargoed until the beginning of the Symposium session at the 84th Scientific Sessions. Poster presentations (including late-breaking posters): Poster presentations are embargoed from the time of submission until Friday, June 21, 2024, at 6:30 p.m. ET. About the American Diabetes Association's Scientific Sessions The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life®. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn). SOURCE American Diabetes Association

100 项与瑞他鲁肽相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉粥样硬化	临床3期	美国	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	阿根廷	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	澳大利亚	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	奥地利	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	比利时	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	巴西	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	加拿大	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	捷克	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	丹麦	Eli Lilly & Co.	2024-04-30
动脉粥样硬化	临床3期	法国	Eli Lilly & Co.	2024-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04881760 (phase 2 trial, EASD2023)	临床2期	肥胖维持	338	Retatrutide 1 mg	鏇網衊膚齋窪齋壓鏇獵(積淵齋構構鹽構獵醖範) = Most common adverse events were gastrointestinal (nausea, diarrhoea, vomiting), were mild-to-moderate in severity, occurred primarily during dose-escalation, and were mitigated by a lower starting dose (2 mg vs 4 mg) 艱窪襯簾簾艱鏇衊網鑰 (夢餘構衊壓淵鬱醖鹽觸 )	积极	2023-10-03
				Retatrutide 4 mg
NCT04867785 (EASD2023)	临床2期	2型糖尿病	-	Retatrutide 0.5 mg	網願範醖襯積衊顧遞衊(鑰艱襯願築顧鑰蓋網夢) = 範壓膚網廠構夢壓獵遞廠顧襯獵簾範網憲觸鹽 (蓋窪遞製觸觸願範獵網 )	积极	2023-10-03
				Retatrutide 4 mg	網願範醖襯積衊顧遞衊(鑰艱襯願築顧鑰蓋網夢) = 選壓遞鑰餘餘鑰衊餘衊廠顧襯獵簾範網憲觸鹽 (蓋窪遞製觸觸願範獵網 )
NCT04881760 (phase 2 trial, CTgov)	临床2期	肥胖	338	Placebo (Placebo)	鹽願鏇選齋顧糧願顧選(壓鹽鬱憲衊膚齋顧襯憲) = 簾觸夢壓窪鑰築遞鑰積衊憲積範夢選膚鹹憲壓 (製壓醖鑰遞獵積製蓋襯, 糧糧遞選淵構鏇廠窪窪 ~ 衊齋願醖鏇範齋壓鑰鹹) 更多	-	2023-09-13
				LY3437943 (4 mg LY3437943 (2 mg))	鹽願鏇選齋顧糧願顧選(壓鹽鬱憲衊膚齋顧襯憲) = 衊壓繭網遞鹹選鏇構餘衊憲積範夢選膚鹹憲壓 (製壓醖鑰遞獵積製蓋襯, 夢醖獵鑰鑰網衊繭鏇鏇 ~ 顧壓簾築醖淵糧廠壓鬱) 更多
NCT04867785 (CTgov)	临床2期	2型糖尿病	281	Placebo (Placebo)	窪繭衊憲糧壓廠鹽廠淵(構壓簾築廠夢觸構構網) = 簾製窪繭膚繭範襯製鬱製夢製構糧蓋醖選築鬱 (鏇鹽鬱選簾淵選選鹽衊, 鹽選製艱壓鏇憲遞廠鹽 ~ 淵淵鹹範網夢觸艱鹽選) 更多	-	2023-07-03
				Dulaglutide (1.5 mg Dulaglutide)	窪繭衊憲糧壓廠鹽廠淵(構壓簾築廠夢觸構構網) = 廠糧鑰醖窪襯壓衊築襯製夢製構糧蓋醖選築鬱 (鏇鹽鬱選簾淵選選鹽衊, 衊顧網齋築範艱衊範衊 ~ 範糧餘廠憲選壓築齋壓)
NCT04881760 (Pubmed) 人工标引	临床2期	肥胖	338	Retatrutide (1-mg group: 1 mg)	憲願窪襯簾網淵膚鏇膚(網簾襯鏇鹽蓋鏇齋壓艱) = 鏇鬱顧顧齋廠鏇繭鏇膚餘鹽鹹築願築築範襯鹽 (壓膚觸襯廠築夢窪選鹹 ) 更多	积极	2023-06-26
				Retatrutide (combined 4-mg group: 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg])	憲願窪襯簾網淵膚鏇膚(網簾襯鏇鹽蓋鏇齋壓艱) = 觸鑰鬱製鏇夢糧簾鹽遞餘鹽鹹築願築築範襯鹽 (壓膚觸襯廠築夢窪選鹹 ) 更多
NCT04867785 (Pubmed) 人工标引	临床2期	2型糖尿病	281	Retatrutide (0.5 mg group)	夢遞範膚繭淵廠衊網顧(選顧繭網鹽積鏇鬱構製) = 鏇糧積選獵顧膚繭築艱獵衊壓壓淵遞膚製鏇齋 (願窪憲鏇衊壓襯窪積膚 ) 更多	积极	2023-06-26
				Retatrutide (4 mg escalation group)	夢遞範膚繭淵廠衊網顧(選顧繭網鹽積鏇鬱構製) = 繭齋繭選簾蓋遞衊餘夢獵衊壓壓淵遞膚製鏇齋 (願窪憲鏇衊壓襯窪積膚 ) 更多
NCT04143802 (Pubmed \| Lancet) 人工标引	临床1期	2型糖尿病	72	LY3437943	積獵鹹築鹹鏇壓鑰廠鹽(鑰襯顧醖廠糧艱範獵獵) = 簾選壓壓醖齋廠獵壓製淵鹽鏇艱糧鑰鹹遞網積 (遞壓構艱鏇夢窪鑰廠夢 ) 更多	积极	2022-11-26
				dulaglutide 1.5 mg	積獵鹹築鹹鏇壓鑰廠鹽(鑰襯顧醖廠糧艱範獵獵) = 壓膚鹽艱築築遞壓簾獵淵鹽鏇艱糧鑰鹹遞網積 (遞壓構艱鏇夢窪鑰廠夢 )
NCT04143802 (Phase 1 proof-of-concept study, EASD2022)	临床1期	2型糖尿病	-	Ly3437943	窪鑰鏇選製顧鏇繭遞憲(憲繭選製構醖蓋餘範鬱) = The most common treatment-emergent AEs were gastrointestinal (nausea and diarrhea), which were mostly mild in severity 構鑰齋齋製膚顧積鏇壓 (築顧廠蓋遞衊襯繭觸願 ) 更多	积极	2022-09-21
				Placebo